World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
105
Citations
42639
World Ranking
6747
National Ranking
3563

Overview

Allan Lipton is affiliated with the Penn State Milton S. Hershey Medical Center in the United States. Their research spans several areas within medicine, with a notable focus on oncology. The main field of study for Lipton is Medicine, with a significant number of publications in Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Cancer Research, and Molecular Biology.

Their work frequently addresses topics including Radiopharmaceutical Chemistry and Applications, Cancer Immunotherapy and Biomarkers, Bone Health and Treatments, Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, Global Cancer Incidence and Screening, and Prostate Cancer Treatment and Research.

Lipton has contributed to a variety of recent research articles, including:

  • Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval, 2022, Journal of bone oncology
  • Oncobiology and treatment of breast cancer in young women, 2022, Cancer and Metastasis Reviews
  • Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types, 2022, Cellular and Molecular Life Sciences
  • Diagnostic delays in breast cancer among young women: An emphasis on healthcare providers, 2023, The Breast
  • Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases, 2020, Cancers

Their frequent coauthors include Suhail M. Ali, Kim Leitzel, Luís Costa, Prashanth Moku, and Hyma Polimera.

Lipton publishes regularly in journals such as Journal of Clinical Oncology, Cancer Research, Journal of bone oncology, Cancer and Metastasis Reviews, and The Breast.

Best Publications

  • Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

    Alison T. Stopeck;Allan Lipton;Jean Jacques Body;Guenther G. Steger

  • Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

    Mark D. Pegram;Allen Lipton;Daniel F. Hayes;Barbara L. Weber

  • Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

    James R. Berenson;Alan Lichtenstein;Lester Porter;Meletios A. Dimopoulos

  • American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer

    Bruce E. Hillner;James N. Ingle;Rowan T. Chlebowski;Julie Gralow

  • Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases

    Gabriel N. Hortobagyi;Richard L. Theriault;Lester Porter;Douglas Blayney

  • Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.

    Allan Lipton;Richard L. Theriault;Gabriel N. Hortobagyi;Joseph Simeone

  • Platelets as a source of fibroblast growth-promoting activity.

    Nancy Kohler;A. Lipton

  • Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.

    James R. Berenson;Alan Lichtenstein;Lester Porter;Meletios A. Dimopoulos

  • Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.

    Gabriel N. Hortobagyi;Richard L. Theriault;Allan Lipton;Lester Porter

  • Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled Trial

    Richard L. Theriault;Allan Lipton;Gabriel N. Hortobagyi;Richard Leff

  • Pathologic fractures correlate with reduced survival in patients with malignant bone disease.

    Fred Saad;Allan Lipton;Richard Cook;Yin Miao Chen

  • A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.

    Jean Jacques Body;Thierry Facon;Robert E. Coleman;Allan Lipton

  • Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: A double-blind, randomized dose-response study

    James R. Berenson;Lee S. Rosen;Anthony Howell;Lester Porter

  • Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors

    Janet E. Brown;Richard J. Cook;Pierre Major;Pierre Major;Allan Lipton

  • Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid

    Robert E. Coleman;Pierre Major;Allan Lipton;Janet E. Brown

  • American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple Myeloma

    James R. Berenson;Bruce E. Hillner;Robert A. Kyle;Ken Anderson

  • Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates

    Karim Fizazi;Allan Lipton;Xavier Mariette;Jean-Jacques Body

  • Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

    Allan Lipton;Karim Fizazi;Alison T. Stopeck;David H. Henry

  • Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel

    M. Aapro;P. A. Abrahamsson;J. J. Body;R. E. Coleman

  • American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer

    Bruce E. Hillner;James N. Ingle;James R. Berenson;Nora A. Janjan

Frequent Co-Authors

Robert E. Coleman
Robert E. Coleman University of Sheffield
Laurence M. Demers
Laurence M. Demers Pennsylvania State University
Richard J. Cook
Richard J. Cook University of Waterloo
Fred Saad
Fred Saad University of Montreal
Jean-Jacques Body
Jean-Jacques Body Université Libre de Bruxelles
Matthew R. Smith
Matthew R. Smith Harvard University
Karim Fizazi
Karim Fizazi University of Paris-Saclay
Vernon M. Chinchilli
Vernon M. Chinchilli Pennsylvania State University
Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
Evangelos Terpos
Evangelos Terpos National and Kapodistrian University of Athens

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Medicine in the USA offers many rewarding career options beyond just the traditional MD. For those interested in patient care and healthcare leadership, nursing school online provides a flexible, accessible path. Online programs make it easier for working professionals or those balancing family commitments to advance their education.

Many registered nurses now seek higher qualifications to expand their clinical and leadership roles. Completing an rn to bsn online is a popular choice, providing upgraded skills and better job prospects. Those targeting advanced practice or research roles may consider an online phd in nursing, opening doors in teaching, policy, and advanced clinical work.

Not a nurse yet? Direct-entry programs are designed for those from non-nursing backgrounds. The direct entry np programs for non nurses online let career changers enter the nurse practitioner field through intensive, accelerated study.

Best Scientists Citing Allan Lipton

Trending Scientists